S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$0.01
+257.1%
$0.00
$0.00
$0.05
$663K1.893,896 shs20,000 shs
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
$0.77
$0.19
$8.69
$291.29M1.05763,526 shs32,246 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$0.73
-6.4%
$0.70
$0.38
$1.15
$26.72M0.4833,701 shs8,346 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.18
$0.20
$0.09
$3.59
$10.01M2.172.44 million shs801,588 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$0.32
+3.2%
$0.41
$0.28
$1.26
$2.01M-0.8163,308 shs29,993 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00%0.00%-20.00%+154.55%-94.40%
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
0.00%0.00%0.00%0.00%+3,136.08%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
+5.41%+9.00%+18.18%+11.94%-26.42%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-6.25%+16.18%-22.98%+6.29%-93.21%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
+4.81%-14.84%-11.87%-37.88%-67.91%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.4138 of 5 stars
3.35.00.00.03.02.51.3
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.1354 of 5 stars
0.03.00.00.01.90.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/A
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
N/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.50
Moderate Buy$2.75274.66% Upside
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
1.75
ReduceN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest GRTX, QLGN, FBRX, CBIO, and ACUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2024
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$2.75
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$1.56M0.43N/AN/AN/A
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
$790K0.00N/AN/A($0.78) per share0.00
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$0.97 per shareN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$4.98M0.40N/AN/A($0.41) per share-0.78

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
-$880KN/A0.00N/AN/AN/AN/AN/A
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$31.48M-$1.04N/AN/AN/AN/A-94.27%-81.36%5/20/2024 (Estimated)
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$1.41N/AN/AN/AN/A-137.47%5/9/2024 (Estimated)
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$13.42MN/A0.00N/AN/AN/A-841.99%-137.02%5/21/2024 (Estimated)

Latest GRTX, QLGN, FBRX, CBIO, and ACUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q4 2023
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A-$0.04-$0.04-$0.04N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/A
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/A
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
N/A
2.88
2.88
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
10.45
10.45
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
4.36
4.36
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
0.28
0.28

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
966.35 million52.95 millionNot Optionable
Catalyst Biosciences, Inc. stock logo
CBIO
Catalyst Biosciences
737.98 million36.87 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
936.40 million32.56 millionOptionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
3154.39 million50.64 millionOptionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
316.31 million5.94 millionNot Optionable

GRTX, QLGN, FBRX, CBIO, and ACUR Headlines

SourceHeadline
Qualigen Announced An Agreement With Marizyme To Commercialize DuraGraftQualigen Announced An Agreement With Marizyme To Commercialize DuraGraft
markets.businessinsider.com - April 16 at 9:47 AM
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
finance.yahoo.com - April 16 at 9:47 AM
Qualigen presents preclinical novel cancer inhibitors at AACR 2024Qualigen presents preclinical novel cancer inhibitors at AACR 2024
uk.investing.com - April 12 at 9:35 AM
Qualigen Therapeutics Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
globenewswire.com - April 10 at 8:00 AM
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
globenewswire.com - April 9 at 8:00 AM
Qualigen Therapeutics Inc Ordinary Shares QLGNQualigen Therapeutics Inc Ordinary Shares QLGN
morningstar.com - February 22 at 3:38 PM
Qualigen Therapeutics Inc (QLGN)Qualigen Therapeutics Inc (QLGN)
uk.investing.com - February 7 at 11:54 PM
QLGN: Dosing Begins in Phase 1 Trial of QN-302…QLGN: Dosing Begins in Phase 1 Trial of QN-302…
finance.yahoo.com - November 27 at 6:06 PM
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
finance.yahoo.com - November 14 at 8:23 PM
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsQualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
finance.yahoo.com - November 7 at 9:19 AM
Poster Highlighting Qualigen Therapeutics Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
finance.yahoo.com - October 23 at 1:03 PM
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
finance.yahoo.com - September 27 at 1:05 PM
Qualigen Therapeutics Inc (7R9.DU)Qualigen Therapeutics Inc (7R9.DU)
ca.finance.yahoo.com - September 2 at 12:01 AM
QLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23…QLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23…
finance.yahoo.com - August 30 at 6:57 PM
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsQualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
finance.yahoo.com - August 17 at 6:08 PM
Qualigen Therapeutics GAAP EPS of -$0.69, revenue of $1.62MQualigen Therapeutics GAAP EPS of -$0.69, revenue of $1.62M
msn.com - August 15 at 2:55 PM
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
finance.yahoo.com - August 15 at 2:55 PM
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsQualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
finance.yahoo.com - August 1 at 11:57 AM
Qualigen Therapeutics Divests FastPack® Diagnostics BusinessQualigen Therapeutics Divests FastPack® Diagnostics Business
finance.yahoo.com - July 24 at 8:43 AM
QLGN: Data for Pan-RAS Platform Presented at ASCO…QLGN: Data for Pan-RAS Platform Presented at ASCO…
finance.yahoo.com - June 14 at 7:12 PM
Poster Highlighting Qualigen Therapeutics Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
technews.tmcnet.com - June 6 at 9:10 AM
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingPoster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
finance.yahoo.com - June 5 at 1:08 PM
Qualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61MQualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61M
seekingalpha.com - May 18 at 9:54 AM
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023
finance.yahoo.com - May 16 at 10:33 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acura Pharmaceuticals logo

Acura Pharmaceuticals

OTCMKTS:ACUR
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Catalyst Biosciences logo

Catalyst Biosciences

NASDAQ:CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Forte Biosciences logo

Forte Biosciences

NASDAQ:FBRX
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Galera Therapeutics logo

Galera Therapeutics

NASDAQ:GRTX
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Qualigen Therapeutics logo

Qualigen Therapeutics

NASDAQ:QLGN
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.